The ISDC Issues Annual Report on Federal Suspension and Debarment Activities and Trends
Client Alert | 1 min read | 04.19.22
On April 18, 2022, the Interagency Suspension and Debarment Committee (ISDC) issued its annual report to Congress on federal suspension and debarment activities for Fiscal Year (FY) 2020. During FY 2020, the ISDC continued to focus on promoting the fundamental fairness of the suspension and debarment process, increasing transparency and consistency, enhancing suspension and debarment practices and alternatives, and encouraging more effective compliance and ethics programs by government contractors and nonprocurement participants. The ISDC also formed a subcommittee to provide recommendations and assistance to the Federal Acquisition Regulatory (FAR) Counsel drafting team to better align suspension and debarment procedures in the FAR with the Nonprocurement Common Rule (NCR).
Despite the COVID-19 pandemic, the report notes that the number of debarments in FY 2020 increased from FY 2019. However, suspensions, proposed debarments, and referrals of new matters all decreased, which was a result of several factors, including delays in mail service, travel restrictions, and postponements in court proceedings. With the exception of pre-notice letters, the metrics also indicate that agencies relied more heavily on alternatives to suspension and debarment, such as administrative agreements, voluntary exclusions, post-notice engagements, and declinations. Notably, the agencies that executed alternatives to suspension and debarment varied from FY 2019, demonstrating that the government applies administrative remedies based on the particular facts presented in each case.
Contacts
Insights
Client Alert | 6 min read | 04.29.26
CMS Seeks to Expand Interoperability Requirements to Drug Pre-Authorization (FAQ)
On April 10, 2026, the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule (2026 CMS Interoperability Standards and Prior Authorization for Drugs, or CMS-0062-P) outlining the agency’s plans to impose new interoperability requirements on payors participating in certain Medicare and Medicaid programs. As described by the agency in a recent press release, the proposed rule “builds on” prior rulemaking by clarifying and enhancing interoperability requirements for payors’ prior authorization processes, specifically those associated with coverage requests for pharmaceutical therapies.
Client Alert | 8 min read | 04.27.26
Client Alert | 5 min read | 04.27.26
Drift Protocol Exploit: Why “Social Trust” Is the Newest Cybersecurity Gap
Client Alert | 4 min read | 04.27.26
Gaming Addiction Litigation: Turner v. Epic Games & Roblox and What It Means for the Industry




